(19)
(11) EP 1 257 665 A2

(12)

(88) Date of publication A3:
29.08.2002

(43) Date of publication:
20.11.2002 Bulletin 2002/47

(21) Application number: 01907219.8

(22) Date of filing: 14.02.2001
(51) International Patent Classification (IPC)7C12Q 1/68, C12N 15/11, C12N 15/10
(86) International application number:
PCT/US0104/732
(87) International publication number:
WO 0106/1030 (23.08.2001 Gazette 2001/34)
(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 14.02.2000 US 504653

(71) Applicants:
  • Cytoclonal Pharmaceutics, Inc.
    Dallas, Tx 75235 (US)
  • University of Texas at Dallas,Department of Molecular and Cell Biology
    Richardson, Tx 75083-0688 (US)
  • Laboratory of Experimental Carcinogenesis,National Cancer Institute/NIH
    Bethesda, MD 20892-4285 (US)

(72) Inventors:
  • Cytoclonal Pharmaceutics, Inc.
    Dallas, Tx 75235 (US)
  • University of Texas at Dallas,Department of Molecular and Cell Biology
    Richardson, Tx 75083-0688 (US)
  • Laboratory of Experimental Carcinogenesis,National Cancer Institute/NIH
    Bethesda, MD 20892-4285 (US)

(74) Representative: Stark, Amanda Jane et al
Abel & Imray,20 Red Lion Street
London WC1R 4PQ
London WC1R 4PQ (GB)

   


(54) LIBRARIES OF OPTIMUM SUBSEQUENCE REGIONS OF mRNA AND GENOMIC DNA FOR CONTROL OF GENE EXPRESSION